Beyond TKIs: Synthetic Lethal Approaches and Targeted Therapies to Watch in Lung Cancer
Leveraging synthetic lethal approaches in lung cancer with new targets and agents may be a promising avenue of investigation.
Related Articles
OncLive’s FDA Approval Report: The Regulatory Rundown for January 2025
Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.
Direct Oral Anticoagulants in Extended Treatment of Venous… : Oncology Times
An abstract is unavailable.
‘Call to action’: Head and neck cancer trials in US becoming less diverse
Despite focused efforts to improve the diversity of clinical trials, representation in research into head and neck cancer has become less equitable over the past…
8 pictures to help you determine if a breast lump is cause for concern
Lumps and bumps are often early signs of breast cancer. These pictures of breast cancer bumps show you what to look for to determine if…
CAR T-cell Therapy for B-ALL
A panelist discusses how CAR-T cell therapy patient selection involves evaluating disease characteristics like relapse/refractory status and tumor burden, patient-specific factors including performance status and…
ENVISION Trial of UGN-102 Shows Durable Responses in LG-IR-NMIBC
Data from the phase 3 ENVISION trial demonstrate the potential of UGN-102 as an effective and durable nonsurgical treatment for patients with low-grade, intermediate-risk non–muscle-invasive…
Gemogenovatucel-T Receives FDA RMAT Designation for Advanced HRP Ovarian Cancer
The FDA granted RMAT designation to gemogenovatucel-T for maintenance treatment after frontline chemotherapy in advanced HRP ovarian cancer.
Transforming Cancer Care Through Data: How Texas Colon & Rectal Specialists Enhances Outcomes, Experiences, and Efficiency
How Texas Colon & Rectal Specialists enhance outcomes, experiences, and efficiency data-driven care to improve patient outcome
Zenocutuzumab exhibits efficacy in NRG 1 fusion-positive cancers
Zenocutuzumab exhibited efficacy among patients with NRG1 fusion-positive cancers, according to phase 2 data published in The New England Journal of Medicine.Nearly one-third of the…
Type II JAK Inhibitor AJ1-11095 Under Phase 1 Investigation in Myelofibrosis
AJ1-11095 is being evaluated in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia.